X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
egfr-tki (437) 437
index medicus (310) 310
oncology (306) 306
humans (303) 303
gefitinib (262) 262
mutation (224) 224
lung cancer (218) 218
chemotherapy (200) 200
lung neoplasms - drug therapy (197) 197
erlotinib (185) 185
female (165) 165
epidermal growth factor (159) 159
carcinoma, non-small-cell lung - drug therapy (151) 151
nsclc (150) 150
lung cancer, non-small cell (137) 137
male (137) 137
lung neoplasms - genetics (136) 136
open-label (134) 134
middle aged (129) 129
respiratory tract diseases (129) 129
cancer (124) 124
aged (120) 120
acquired-resistance (117) 117
protein kinase inhibitors - therapeutic use (117) 117
receptor, epidermal growth factor - genetics (114) 114
lung neoplasms - pathology (113) 113
carcinoma, non-small-cell lung - genetics (109) 109
tyrosine (108) 108
receptor, epidermal growth factor - antagonists & inhibitors (104) 104
non-small cell lung cancer (103) 103
adenocarcinoma (100) 100
antineoplastic agents - therapeutic use (97) 97
1st-line treatment (94) 94
carcinoma, non-small-cell lung - pathology (92) 92
respiratory system (89) 89
adult (85) 85
cell lung-cancer (82) 82
egfr mutation (82) 82
egfr (80) 80
growth-factor receptor (79) 79
tyrosine kinase inhibitors (77) 77
aged, 80 and over (74) 74
care and treatment (71) 71
drug resistance (71) 71
kinases (71) 71
mutations (70) 70
resistance (70) 70
egfr tki (67) 67
prognosis (67) 67
quinazolines - therapeutic use (67) 67
protein kinase inhibitors - pharmacology (64) 64
analysis (63) 63
cancer therapies (63) 63
genetic aspects (63) 63
treatment outcome (62) 62
tumors (62) 62
cell line, tumor (60) 60
therapy (60) 60
animals (59) 59
multicenter (59) 59
neoplasms. tumors. oncology. including cancer and carcinogens (56) 56
epidermal growth factor receptors (55) 55
lung neoplasms (54) 54
patients (54) 54
afatinib (53) 53
antineoplastic agents - pharmacology (51) 51
lung neoplasms - mortality (51) 51
protein-tyrosine kinase (51) 51
research (51) 51
drug resistance, neoplasm (49) 49
t790m mutation (49) 49
disease-free survival (48) 48
egfr-tki resistance (48) 48
retrospective studies (48) 48
cell biology (47) 47
health aspects (47) 47
quinazolines - pharmacology (47) 47
receptor, epidermal growth factor - metabolism (47) 47
lung neoplasms - metabolism (46) 46
non-small cell lung carcinoma (46) 46
survival (46) 46
adenocarcinoma - drug therapy (45) 45
erbb receptors - genetics (45) 45
expression (45) 45
hematology, oncology and palliative medicine (45) 45
osimertinib (44) 44
neoplasm staging (43) 43
drug resistance, neoplasm - genetics (42) 42
pharmacology & pharmacy (42) 42
erlotinib hydrochloride (41) 41
metastasis (41) 41
lung cancer, small cell (40) 40
apoptosis (39) 39
inhibitors (39) 39
carcinoma, non-small-cell lung - mortality (38) 38
research paper (38) 38
mice (37) 37
pulmonary/respiratory (37) 37
lung adenocarcinoma (36) 36
tyrosine kinase inhibitor (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (621) 621
Chinese (24) 24
French (4) 4
Hungarian (3) 3
Japanese (3) 3
Korean (3) 3
Czech (1) 1
German (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lung Cancer, ISSN 0169-5002, 11/2019, Volume 137, pp. 85 - 93
EGFR-targeted tyrosine kinase inhibitors (TKIs) have been the standard treatment for non-small cell lung cancer patients with mutations. However, most patients... 
PD-L1 | Pneumonitis | EGFR-TKI | Lung cancer
Journal Article
Oncotarget, ISSN 1949-2553, 08/2019, Volume 10, Issue 50, p. 5152
The AXL receptor tyrosine kinase is involved in signal transduction in malignant cells. Recent studies have shown that the AXL upregulation underlies epidermal... 
Journal Article
11/2011
EGFR TKIs are standard therapy for advanced NSCLC. In order to define their role in early disease, we implemented a phase II trial of neoadjuvant gefitinib in... 
lung cancer | neoadjuvant | EGFR TKI | NSCLC | 0992 | histopathological response | response | molecular response | EGFR | Intratumoural heterogeneity | ischemia
Dissertation
Oncotarget, 03/2018, Volume 9, Issue 24, pp. 16807 - 16821
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, ISSN 0923-7534, 10/2014, Volume 25, Issue 10, pp. 1935 - 1940
Journal Article
Zhongguo fei ai za zhi = Chinese journal of lung cancer, 01/2019, Volume 22, Issue 1, pp. 52 - 56
Journal Article
CANCER DISCOVERY, ISSN 2159-8274, 06/2017, Volume 7, Issue 6, pp. 575 - 585
We report a HER2(T798I) gatekeeper mutation in a patient with HER2(L869R)-mutant breast cancer with acquired resistance to neratinib. Laboratory studies... 
LUNG-CANCER | ACTIVATION | SOLID TUMORS | MECHANISM | ONCOLOGY | EPIDERMAL-GROWTH-FACTOR | ERBB2 | DRUG-RESISTANCE | EGFR-TKI | FACTOR RECEPTOR | KINASE DOMAIN
Journal Article
Lung Cancer, ISSN 0169-5002, 07/2019, Volume 133, pp. 10 - 19
In patients with advanced epidermal growth factor receptor mutation-positive ( m+) non-small cell lung cancer (NSCLC), first-line afatinib significantly... 
EGFR TKI | Afatinib | Long-term responder | NSCLC | Lung cancer, Non-small cell | Analysis
Journal Article
Cancer letters, ISSN 0304-3835, 6/2018, Volume 424, pp. 84 - 96
Non-small cell lung cancer (NSCLC) patients harboring EGFR-activating mutations initially respond to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and have shown... 
EGFR-TKI | HSP70 phosphorylation and degradation | EGFR T790M mutation | Base excision repair | Lung cancer
Journal Article
Chinese Journal of Lung Cancer, ISSN 1009-3419, 2016, Volume 19, Issue 10, pp. 679 - 681
Journal Article
Molecular Carcinogenesis, ISSN 0899-1987, 02/2019, Volume 58, Issue 2, pp. 247 - 257
The aim of this study is to investigate the role of CD147 in glucose metabolic regulation and its association with epidermal growth factor receptor (EGFR)... 
EGFR-TKI treatment sensitivities | F-FDG PET-CT imaging | NSCLC | CD147 | glucose metabolic regulation
Journal Article
by Rong, XZ and Liang, Y and Han, Q and Zhao, Y and Jiang, GY and Zhang, XP and Lin, XY and Liu, Y and Zhang, Y and Han, X and Zhang, MY and Luo, Y and Li, PC and Wei, L and Yan, T and Wang, EH
JOURNAL OF THORACIC ONCOLOGY, ISSN 1556-0864, 10/2019, Volume 14, Issue 10, pp. 1766 - 1783
Introduction: The molecular mechanism underlying the induction of resistance to tyrosine kinase inhibitors (TKIs) via the membranous/cytoplasmic/nuclear... 
OSIMERTINIB | YAP | EGFR-TKI | Hippo pathway | ONCOLOGY | RESPIRATORY SYSTEM | LUNG ADENOCARCINOMA | TKI resistance | EGFR translocation | SIK2 | MUTATIONS | EXPRESSION | AZD9291
Journal Article
Lung Cancer, ISSN 0169-5002, 06/2019, Volume 132, pp. 54 - 58
Osimertinib is a tyrosine kinase inhibitor (TKI) that is an essential agent for the treatment of ( )-mutant non-small-cell lung cancer (NSCLC). However, there... 
EGFR mutation | Non-small-cell lung cancer | Osimertinib | EGFR TKI | T790M | Re-administration | Tyrosine | Epidermal growth factor
Journal Article
Oncotarget, ISSN 1949-2553, 02/2019, Volume 10, Issue 10, pp. 1119 - 1131
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 09/2019, Volume 20, Issue 9, pp. 1183 - 1186
First-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) could induce dramatic tumor responses in non-small-cell lung cancer... 
De novo MET amplification | EGFR mutation | EGFR-TKI | NSCLC | intrinsic resistance | LUNG-CANCER | GEFITINIB | TKI | ONCOLOGY
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.